GlassScriptPhysician profile
Prabhdeep S Sethi
NPI 1154379147
$25,734.47
in general payments reported to CMS, 2019-2025
37 companies · $8,229 in 2025
The $8,229 reported for 2025 was more than what 87% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,275 · 2020: $1,094 · 2021: $5,668 · 2022: $3,094 · 2023: $1,029 · 2024: $1,345 · 2025: $8,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,235 · Food and Beverage: $3,145 · Education: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,234.50 |
| Food and Beverage | $3,144.88 |
| Education | $223.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15,741.76 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $4,196.23 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $898.78 | 2019-2025 | |
| Boston Scientific Corporation | $854.90 | 2019-2025 | Watchman Flx, Watchman Access System |
| Edwards Lifesciences Corporation | $756.77 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $387.14 | 2022-2025 | Verquvo |
| Abiomed | $372.73 | 2019-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.30 | 2019-2025 | Jardiance |
| Medtronic, INC. | $298.87 | 2021-2024 | Micra, Reveal Linq, Corevalve Evolut R |
| Abbott Laboratories | $278.57 | 2022-2025 | Assurity, Jot Dx |
| Pfizer INC. | $241.94 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $191.22 | 2019-2025 | Camzyos, Eliquis |
| W. L. Gore & Associates, INC. | $186.03 | 2020-2025 | Excluder Conformable Aaa Endoprosthesis With Active Control, C3 Delivery System |
| Astrazeneca Pharmaceuticals LP | $138.05 | 2019-2024 | Wainua, Farxiga |
| Scpharmaceuticals INC. | $95.85 | 2023-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $92.84 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $73.13 | 2023-2024 | Inpefa |
| Cvrx, INC. | $66.69 | 2022-2024 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $63.13 | 2019-2021 | |
| Biotronik INC. | $55.71 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $40.15 | 2021-2023 | Arcalyst |
| Penumbra, INC. | $38.75 | 2023 | Indigo System |
| Novo Nordisk INC | $38.00 | 2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $35.76 | 2022-2025 | |
| Irhythm Technologies, INC. | $31.79 | 2022-2023 | Zio Xt Patch |
| Medtronic Vascular, INC. | $31.76 | 2019 | |
| Cardiva Medical, INC. | $25.41 | 2024 | Optowire |
| Bridgebio Pharma, INC. | $25.13 | 2025 | Attruby |
| Baxter Healthcare | $23.14 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Kiniksa Pharmaceuticals International, Plc | $21.07 | 2024 | Arcalyst |
| Chiesi USA, INC. | $20.46 | 2025 | Kengreal |
| Glaxosmithkline, LLC. | $19.41 | 2025 | Arexvy, Shingrix |
| Philips North America LLC | $18.12 | 2020 | |
| Cleerly, INC. | $18.08 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Atricure, INC. | $17.82 | 2025 | Atriclip Laa Exclusion System |
| Amarin Pharma, INC. | $15.61 | 2019 | |
| Shockwave Medical, INC | $15.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prabhdeep Sethi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.